1.95
price down icon3.94%   -0.08
pre-market  Pre-mercato:  1.99   0.04   +2.05%
loading
Precedente Chiudi:
$2.03
Aprire:
$2.01
Volume 24 ore:
15.87M
Relative Volume:
7.98
Capitalizzazione di mercato:
$149.67M
Reddito:
-
Utile/perdita netta:
$-37.34M
Rapporto P/E:
-1.4338
EPS:
-1.36
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
+26.62%
1M Prestazione:
+1.04%
6M Prestazione:
+98.98%
1 anno Prestazione:
+71.05%
Intervallo 1D:
Value
$1.83
$2.0399
Intervallo di 1 settimana:
Value
$1.51
$2.04
Portata 52W:
Value
$0.772
$2.12

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
Nome
Sellas Life Sciences Group Inc
Name
Telefono
(646) 200-5278
Name
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Name
Dipendente
15
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SLS's Discussions on Twitter

Confronta SLS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.95 149.67M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-07-21 Iniziato Cantor Fitzgerald Overweight
2018-11-01 Iniziato Oppenheimer Outperform
2018-04-02 Iniziato H.C. Wainwright Buy
2018-03-19 Aggiornamento Maxim Group Hold → Buy

Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie

pulisher
Jun 18, 2025

SELLAS Life Sciences Holds Annual Stockholders Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 16, 2025

SELLAS Life Sciences: Tons Of Completed Studies (NASDAQ:SLS) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 13, 2025

Insider Buying: VAN NOSTRAND ROBERT L Acquires Additional Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Sellas Life Sciences director Van Nostrand buys $14,800 in stock By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Sellas Life Sciences director Van Nostrand buys $14,800 in stock - Investing.com

Jun 13, 2025
pulisher
Jun 05, 2025

SELLAS adds oncology experts to advisory board By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

SELLAS Life Sciences Expands Scientific Advisory Board with - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

SELLAS Life Sciences Expands Scientific Advisory Board - citybiz

Jun 05, 2025
pulisher
Jun 05, 2025

SELLAS adds oncology experts to advisory board - Investing.com

Jun 05, 2025
pulisher
Jun 05, 2025

Leading Oncology Experts Join SELLAS Advisory Board as Critical AML Trial Results Near - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Acquires 33,878 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Lif - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

SELLAS reports potential colorectal cancer therapy progress By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

SELLAS reports potential colorectal cancer therapy progress - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

Insider Buying: Jane Wasman Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

SELLAS Life Sciences (SLS) Highlights Promising Results for SLS0 - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough at ASCO: SELLAS Drug Shows Powerful Response in Targeted Colorectal Cancer Treatment - Stock Titan

Jun 02, 2025
pulisher
May 26, 2025

National Bank Financial Comments on CVE:SLS FY2026 Earnings - Defense World

May 26, 2025
pulisher
May 23, 2025

Insider Buying: Katherine Kalin Acquires 20,000 Shares of SELLAS Life Sciences Group Inc (SLS) - GuruFocus

May 23, 2025
pulisher
May 23, 2025

US futures and global markets tumble after Trump threatens European Union with 50% tariffs and Apple with 25% tariff - The Globe and Mail

May 23, 2025
pulisher
May 23, 2025

Director Makes Bold Move with Major Stock Purchase in SELLAS Life Sciences Group - TipRanks

May 23, 2025
pulisher
May 20, 2025

Sellas Life Sciences Reports Improved Financial Position - TipRanks

May 20, 2025
pulisher
May 20, 2025

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase - The Manila Times

May 20, 2025
pulisher
May 20, 2025

SELLAS Life Sciences CEO to Reveal Latest Cancer Drug Development Strategy at Major Healthcare Conference - Stock Titan

May 20, 2025
pulisher
May 16, 2025

Sellas doses first paediatric subject with AML in Phase II trial of SLS009 - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

SELLAS advances pediatric AML treatment with Phase 2 trial By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

Sellas Life Sciences Doses 1st Pediatric Patient in Acute Myeloid Leukemia Study - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

SELLAS Life Sciences (SLS) Advances Phase 2 Trial for Pediatric AML | SLS Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

SELLAS advances pediatric AML treatment with Phase 2 trial - Investing.com

May 15, 2025
pulisher
May 15, 2025

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Breakthrough: First Child with Resistant Leukemia Receives New Treatment in Major Clinical Trial - Stock Titan

May 15, 2025
pulisher
May 14, 2025

SELLAS Life Sciences (SLS) Reports Improved Q1 Earnings Amid Fin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

SLS009 Shows Promising Results in Latest AML Trials | SLS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 14, 2025
pulisher
May 13, 2025

SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.

May 12, 2025
pulisher
May 11, 2025

SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 07, 2025

Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.72 - DWinneX

May 07, 2025
pulisher
May 02, 2025

Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX

May 02, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

May 02, 2025
pulisher
Apr 30, 2025

Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Apr 29, 2025
pulisher
Apr 29, 2025

Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 28, 2025

SELLAS reports promising AML treatment in preclinical study - Investing.com

Apr 28, 2025

Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Sellas Life Sciences Group Inc Azioni (SLS) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Wasman Jane
Director
May 30 '25
Buy
1.69
20,000
33,800
30,400
Kalin Katherine Bach
Director
May 22 '25
Buy
1.80
20,000
36,000
41,000
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Capitalizzazione:     |  Volume (24 ore):